Abbott Laboratories Stock

Shares of Abbott Laboratories (NYSE: ABT) popped on Thursday after the healthcare products provider raised its full-year profit forecast.

Image source: Getty Images.

Abbott's sales rose 13% to

Should you stick with a diversified healthcare titan or a specialized high-growth challenger? Here is how Abbott Laboratories (NYSE:ABT) and Glaukos (NYSE:GKOS) stack up for investors looking ahead

Demand for GLP-1 medicines is booming, as these drugs have proven highly effective at treating diabetes, obesity, and other conditions. Investors looking to capitalize on this may turn to the

Choosing between established stability and high-tech growth often defines a portfolio. Whether you prefer the diversified reach of Abbott Laboratories (NYSE:ABT) or the specialized dominance of

Abbott Laboratories (NYSE: ABT) reports second-quarter earnings on July 16, and some investors are trying to determine whether to buy the stock before the report is released or wait for the results.

Although broader equities have performed pretty well this year, recession fears are lingering. After all, we are still dealing with macroeconomic problems and rising inflation. For those especially

When dividend stocks are struggling and trading at reduced valuations, there's a big incentive to load up on them. At lower share prices, not only could they generate better returns, but their

Abbott Laboratories (NYSE: ABT) is offering income investors a rare setup: a yield is approaching 3% while the business continues to grow. The stock isn't a screaming bargain, and rising costs

Investing in high-quality dividend stocks is a great way to earn excellent returns over the long run. It's even better to buy shares of attractive dividend payers on the dip. That's what investors

These are times that can make an investor nervous. Our country is waging a war, while tariffs have disrupted the global economy, with some trade partnerships changing. With so much seemingly

Abbott Laboratories (NYSE: ABT) and Dexcom (NASDAQ: DXCM) are two leading medical device companies that compete against one another in the market for continuous glucose monitoring (CGM) systems.

Abbott Laboratories (NYSE: ABT) more or less met analyst estimates in its first quarter, the results of which were published early Thursday morning. This clearly wasn't good enough for investors, as

Economic downturns cast a wide net across the market, and there's no stock that's completely immune to a recession. However, certain income-oriented healthcare stocks can help investors weather

Stocks that perform well over the long run tend to have several traits, such as a large, growing market where they have a strong presence, solid financial results, and a competitive moat. Investing